For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
A biosimilar is a biologic medical product highly similar to another already approved biological medicine (the 'reference medicine'). Biosimilars are approved according to the same standards of pharmaceutical quality, safety and efficacy that apply to all biological medicines. Biosimilars are officially approved versions of original "innovator" products and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.
According to our (Global Info Research) latest study, the global Biosimilars market size was valued at USD 5893.3 million in 2022 and is forecast to a readjusted size of USD 17930 million by 2029 with a CAGR of 17.2% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Biosimilars market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Global Biosimilars market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Biosimilars market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Biosimilars market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Biosimilars market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Biosimilars
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Biosimilars market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Novartis, Biocon, Biogen and Fresenius Kabi AG, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Biosimilars market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
- Recombinant Glycosylated Proteins
Market segment by Application
- Blood Disorders
- Growth Hormonal Deficiency
- Chronic and Autoimmune Disorders
Major players covered
- Fresenius Kabi AG
- Boehringer Ingelheim
- Merck KgaA
- Eli Lilly
- Teva Pharmaceutical
- Dr. Reddy's Laboratories
- Samsung Biologics
- Chong Kun Dang
- JCR Pharmaceuticals
- Gan & Lee Pharmaceuticals
- Gedeon Richter
- Coherus Bioscience
- Stada Arzneimittel AG
Market segment by region, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Biosimilars product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Biosimilars, with price, sales, revenue and global market share of Biosimilars from 2018 to 2023.
Chapter 3, the Biosimilars competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Biosimilars breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Biosimilars market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Biosimilars.
Chapter 14 and 15, to describe Biosimilars sales channel, distributors, customers, research findings and conclusion.